| MEDICAL RESEARCH COUNCIL Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129710 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods. | 05-24-2012 |
| 20120101256 | MULTISPECIFIC PEPTIDES - The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions. | 04-26-2012 |
| 20120077948 | Methods - The invention relates to a method of making a polypeptide comprising an orthogonal functional group, said orthogonal functional group being comprised by an aliphatic amino acid or amino acid derivative, said method comprising providing a host cell; providing a nucleic acid encoding the polypeptide of interest; providing a tRNA-tRNA synthetase pair orthogonal to said host cell; adding an amino acid or amino acid derivative comprising the orthogonal functional group of interest, wherein said amino acid or amino acid derivative is a substrate for said orthogonal tRNA synthetase, wherein said amino acid or amino acid derivative has an aliphatic carbon backbone; and incubating to allow incorporation of said amino acid or amino acid derivative into the polypeptide of interest via the orthogonal tRNA-tRNA synthetase pair. The invention also relates to certain amino acids, and to polypeptides comprising same. | 03-29-2012 |
| 20120020985 | ANTIBODIES AGAINST IL-17BR - The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease. | 01-26-2012 |
| 20120010126 | RECOMBINANT SURFACTANT PROTEIN D COMPOSITIONS AND METHODS OF USE THEREOF - We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively. | 01-12-2012 |
| 20120010107 | SELECTION BY COMPARTMENTALISED SCREENING - The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, by compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsules; and identifying the compound which binds to or modulates the activity of the target. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development. | 01-12-2012 |
| 20120010098 | SELECTION BY COMPARTMENTALISED SCREENING - The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, by compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsules; and identifying the compound which binds to or modulates the activity of the target. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development. | 01-12-2012 |
| 20120009597 | Biomarker for Barrett's Oesophagus - The present invention relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods. | 01-12-2012 |
| 20110318326 | Compositions and Methods - The invention relates to a method for alleviating the inhibition of neurite outgrowth from a neurone, wherein said neurone comprises a Nogo receptor, said method comprising contacting said neurone with a composition capable of causing phosphorylation of a Nogo receptor, wherein said composition comprises protein kinase A or casein kinase. | 12-29-2011 |
| 20110294137 | Sensor - The invention relates to an ADP binding molecule comprising a polypeptide, said polypeptide comprising amino acid sequence corresponding to at least amino acids 11 to 310 of SEQ ID NO:1, wherein said polypeptide comprises a substitution relative to SEQ ID NO:1 at amino acid C287, and wherein said polypeptide comprises a further cysteine residue for attachment of at least one reporter moiety, and wherein said polypeptide has at least 68% sequence identity to SEQ ID NO:1 at the amino acid residues corresponding to those shown in column III of table A. | 12-01-2011 |
| 20110275068 | METHOD - The present invention relates to a combination method for A) measuring the copy number frequency of one or more nucleic acid sequences in a sample; and B) analysing the sequence of at least part of the nucleic acid sequence(s), wherein method A) comprises the steps of:
| 11-10-2011 |
| 20110269647 | METHOD - There is described a method for identifying an interaction between an RNA and an RNA binding protein in a biological sample, comprising the steps of: a) contacting the biological sample with an agent that creates a covalent bond between the RNA and the RNA binding protein; b) fragmenting said RNA; c) ligating a first adapter to the fragmented RNA; d) hybridising a reverse transcription primer to said first adapter and reverse transcribing said cross-linked RNA; e) circularising the transcribed cDNA; f) linearising the circularised cDNA; and g) determining the sequence of one or more of the cDNAs. | 11-03-2011 |
| 20110256062 | Methods - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems. | 10-20-2011 |
| 20110136922 | ACTIVATION INDUCED DEAMINASE (AID) - The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide. | 06-09-2011 |
| 20110105403 | PEPTIDES - The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule. | 05-05-2011 |
| 20110038892 | COMPLEXING SYSTEM - The invention relates to a complexing system comprising two polypeptide helices derived from a SNAP protein; one polypeptide helix derived from syntaxin; one polypeptide helix derived from synaptobrevin or a homolog thereof; and one or more cargo moieties attached to the polypeptide helices, wherein the four polypeptide helices can form a stable SNARE complex. The invention also relates to a method of producing the complexing system and the use of the complexing system. | 02-17-2011 |
| 20110027829 | Methods and Compositions - The invention relates to a tRNA synthetase capable of binding N | 02-03-2011 |
| 20110021612 | NK1 FRAGMENT OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) AND VARIANTS THEREOF, AND THEIR USE - The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure. | 01-27-2011 |
| 20100317540 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods. | 12-16-2010 |
| 20100240615 | NITRIC OXIDE DONORS - The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria. | 09-23-2010 |
| 20100234234 | Methods and Devices for Detecting Structural Changes in a Molecule Measuring Electrochemical Impedance - The invention relates to a method of detecting a structural change in a molecule, said molecule being attached to a surface, said surface being electrically conductive, wherein the phase of the electrochemical impedance at said surface is monitored, and wherein a change in the phase in the electrochemical impedance at said surface indicates a change in the structure of said molecule. The invention further relates to methods for making arrays having molecules such as, polypeptides attached to electrically conductive surfaces such as electrodes, and to arrays. | 09-16-2010 |
| 20100233751 | APPARATUS AND METHOD FOR MONITORING CULTURES - Disclosed is a bubble excluder device ( | 09-16-2010 |
| 20100210479 | METHOD OF SYNTHESIS AND TESTING OF COMINATORIAL LIBRARIES USING MICROCAPSULES - Methods for use in the synthesis and identification of molecules which bind to a target component of a biological system or modulate the activity of a target are described. | 08-19-2010 |
| 20100190201 | Methods - The invention relates to a method of detecting an altered behaviour in a population of cells, said method comprising determining at least one of the following characteristics of the population of cells; (i) the proportion of stem cells, proliferating cells and differentiated cells in said cell population; or (ii) the size of stem cell clusters in said cell population; or (iii) the separation of stem cell clusters in said cell population; and comparing said at least one characteristic to a reference value, wherein a difference between the determined value and the reference value indicates an altered behaviour in said population of cells. Preferably the cells are mammalian, more preferably human epithelial cells, more preferably human epidermal cells. | 07-29-2010 |
| 20100184071 | COMPARTMENTALIZED SELF TAGGING - The present invention relates to the development of a novel method for the selection of nucleic acid processing and other enzymes. In particular the invention relates to a method for the selection of nucleic acid polymerases and other enzymes with desired properties based on the method of compartmentalized self-tagging. | 07-22-2010 |
| 20100173972 | METHODS AND USES RELATED TO RHBDL4 - The invention relates to a method of identifying a modulator of RHBDL4, said method comprising (i) providing a first and second sample of cells; (ii) contacting said first sample of cells with a candidate modulator of RHBDL4; (iii) measuring epidermal growth factor receptor (EGFR) transactivation in said first and second samples of cells, wherein a difference between the transactivation measured in said first and second samples of cells identifies said candidate modulator of RHBDL4 as a modulator of RHBDL4. The invention also relates to RHBDL4 protease assays and to uses of RHBDL4 protease and methods of cleavage of RHBDL4 substrates. | 07-08-2010 |
| 20100130731 | CRYSTAL STRUCTURE OF P53 MUTANTS AND THEIR USE - The invention relates to crystals of p53 which have mutations in the β-sandwich region at positions 220, 143 or 270. The structures may be used for computer-based drug design to identify ligands which can bind within the β-sandwich region in order to stabilize the proteins. | 05-27-2010 |
| 20100105565 | Evolved Orthogonal Ribosomes - There is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of: providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes; providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons; assaying the translation of the of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA, wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA; and orthogonal ribosomes incorporating such rRNA molecules. | 04-29-2010 |
| 20100047823 | Polypeptides - The use of polypeptides capable of binding to PtdIns(3,4)P | 02-25-2010 |
| 20100035868 | METHODS OF TREATMENT OF UTERINE PATHOLOGICAL CONDITIONS - A method of treating or preventing a pathological condition of the uterus in an individual the method comprising administering to the individual any one or more of an inhibitor of cyclooxygenase-2 (COX-2), an inhibitor of prostaglandin E synthase (PGES), or an EP2 or EP4 receptor antagonist. Typically, the pathological condition is uterine cancer, fibroids or endometriosis. | 02-11-2010 |
| 20100035767 | POLYMERASE - The present invention relates to an engineered polymerase with an expanded substrate range characterized in that the polymerase is capable of incorporating an enhanced occurrence of detection agent-labeled nucleotide analogue into nucleic acid synthesized by that engineered polymerase as compared with the wild type polymerase from which it is derived. | 02-11-2010 |
| 20100034786 | Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells - The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PBK alpha or PBK delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PBK inhibitors, PBK inhibitors for particular uses, and kits. | 02-11-2010 |
| 20100032374 | PHOSPHATE BINDING MATERIALS AND THEIR USES - Phosphate binding materials and compositions comprising them which are solid ligand-modified poly oxo-hydroxy metal ion materials are disclosed that are based on ferric iron oxo-hydroxides modified with carboxylic acid ligands, or ionised forms thereof. These materials are made and tested in the examples provided in the application to demonstrate that they can bind phosphate in in vitro and in in vivo studies. | 02-11-2010 |
| 20090325867 | RECEPTOR-SPECIFIC TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) VARIANTS - The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and/or 199V; preferably also 201R, 213W and 215D, and/or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same. | 12-31-2009 |
| 20090325815 | PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE - Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from rearranged V-gene sequences of unimmunised mammal. Synthetic or artificial libraries are described and shown to be useful. | 12-31-2009 |
| 20090317822 | SELECTION OF INTRACELLULAR IMMUNOGLOBULINS - A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment. | 12-24-2009 |
| 20090307784 | Methods of Analysing Cell Behaviour - The invention related to a method of imaging a clonal cell line comprising providing a test animal comprising a marker gene, inducing inheritable activation of said marker in at least one cell of said test animal, wherein inheritable activation is induced in fewer than 1 in 27 cells in the tissue of interest, incubating the test animal, and visualising those clonal cells which express the marker gene as a result of the inheritable activation. In particular the invention concerns-methods where the tissue is epidermis, and wherein the visualisation is by confocal microscopy such as wholemount confocal microscopy. The invention also relates to toxicity and carcinogenicity testing using such methods. | 12-10-2009 |
| 20090306187 | Modulators of Itch Ubiquitinase Activity - The present invention relates to the identification of new drug targets for therapy of disorders including cancer. In particular, the present invention relates to inhibition of the E3 ubiquitin ligase, Itch, as a means for treating disorders. Furthermore, the present invention relates to the regulation of p63 and p73 stability in cells. In particular, the invention relates to the modulation of the regulation of p63 and p73 stability in cells through modulation of the expression or activity of Itch. Moreover, the invention relates to the use of Itch as a target for the development of agents capable of modulating p63 or p73 stability and especially agents capable of modulating the interaction of Itch and p63 or p73. Such agents may be useful in therapeutic applications including cancer treatment and modulation of skin differentiation. | 12-10-2009 |
| 20090305345 | POLYMERASE - The present invention relates to an engineered polymerase characterized in that the polymerase exhibits an enhanced ability to process nucleic acid in the presence of environmental and biological inhibitors compared to wild type DNA polymerase. | 12-10-2009 |
| 20090305292 | DNA POLYMERASE - The present invention relates to DNA polymerases. In particular the invention relates to a method for the generation of DNA polymerases exhibiting a relaxed substrate specificity. Uses of mutant polymerases produced using the methods of the invention are also described. | 12-10-2009 |
| 20090286237 | Diagnostic Kits and Methods for Oesophageal Abnormalities - The invention relates to kits and methods for aiding the diagnosis of Barrett's oesophagus or Barrett's associated dysplasia. Preferred is a method comprising assaying cells from the surface of a subject's oesophagus for a non-squamous cellular marker, wherein detection of such a marker indicates increased likelihood of the presence of Barrett's or Barrett's associated dysplasia, preferably wherein said sample of cells is not directed to a particular site within the oesophagus. The invention also encompasses a method comprising sampling the cellular surface of the oesophagus of said subject. The invention also relates to a kit comprising a swallowable device comprising abrasive material capable of collecting cells from the surface of the oesophagus, together with printed instructions for its use in detection of Barrett's oesophagus or Barrett's associated dysplasia. Preferably said device comprises a capsule sponge. | 11-19-2009 |
| 20090275635 | SCREENING METHOD - The invention provides a method of modulating Wnt signalling comprising modulating Trabid activity. Preferably modulating Trabid activity comprises inhibiting; Trabid activity. The invention also provides a method of reducing TCF transcription, said method comprising reducing Trabid activity. A method for identifying a-modulator of Trabid said method comprising; providing a Trabid substrate comprising a detectable moiety coupled to a tag moiety by ubiquitin; immobilising first and second portions of said substrate; adding a candidate modulator to the first said portion; contacting first and second portions with Trabid; incubating to allow Trabid action, assaying cleavage of ubiquitin by separation of tag from detectable moiety, wherein separation of an amount of detectable moiety from said first portion which is different from the amount of detectable moiety separated from said second portion identifies said candidate as a modulator of Trabid. The invention provides uses of Trabid and of Trabid inhibitors as-medicaments. | 11-05-2009 |
| 20090264383 | Inhibitor of Adenylyl Cyclase for Treating a Disorder of the Circadian Rhythm - The invention relates to use of a composition comprising an inhibitor of adenylyl cyclase in the elongation of circadian rhythm, a method of extending the period of circadian rhythm in a subject, said method comprising administering to said subject an inhibitor of adenylyl cyclase, and to adenylyl cyclase inhibitor for use in the treatment of a disorder of the circadian rhythm. Preferably the inhibitor is a P-site inhibitor, preferably 9-(tetrahydrofuryl)-adenine. The composition may further comprise a JNK inhibitor. | 10-22-2009 |
| 20090246853 | DIRECTED EVOLUTION METHOD - We describe a method of selecting an enzyme having replicase activity, the method comprising the steps of: (a) providing a pool of nucleic acids comprising members each encoding a replicase or a variant of the replicase; (b) subdividing the pool of nucleic acids into compartments, such that each compartment comprises a nucleic acid member of the pool together with the replicase or variant encoded by the nucleic acid member; (c) allowing nucleic acid replication to occur; and (d) detecting amplification of the nucleic acid member by the replicase. Methods for selecting agents capable of modulating replicase activity, and for selecting interacting polypeptides are also disclosed. | 10-01-2009 |
| 20090191556 | Method - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 07-30-2009 |
| 20090181863 | SCD Fingerprints - This invention relates to methods of testing, diagnosing, monitoring, prognostically stratifying and classifying disease, disorders and other medical conditions and physiological states through the detection and analysis of soluble CD antigens in a body fluid sample. | 07-16-2009 |
| 20090156457 | METHODS AND MEANS FOR SCREENING FOR RHOMBOID ACTIVITY - This invention relates to methods of screening for rhomboid modulating compounds using a substrate polypeptide has a core domain comprising a rhomboid cleavable TMD sequence linked to an upstream tag sequence. The core domain sequence is not susceptible to cleavage by non-rhomboid proteases so products of rhomboid dependent proteolysis products may be detected by determining the presence of the tag sequence. Rhomboid modulating compounds identified by the present methods may be useful in a range of therapeutic applications. | 06-18-2009 |
| 20090155810 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods. | 06-18-2009 |
| 20090110685 | Treatment and prevention of viral infections - Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection. | 04-30-2009 |
| 20090075270 | Products and Methods Relating to the Use of the Endoribonuclease Kid/PemK - The invention relates to a method for engineering a nucleic acid for expression in the presence of Kid/PemK endoribonuclease comprising (i) screening the nucleotide sequence of the nucleic acid for the sequence UUACU or TTACT (ii) mutating said sequence such that there are no longer any occurrences of UUACU or TTACT. The invention also relates to a method of making a ribonucleic acid resistant to Kid/PemK endoribonuclease, said method comprising (a) providing a nucleic acid; (b) screening the nucleic acid for the nucleotide sequence UUACU or TTACT; (c) mutating said sequence such that there are no longer any occurrences of UUACU or TTACT; wherein when the nucleic acid of (a) is a deoxyribonucleic acid, said method further comprises (d) transcribing said deoxyribonucleic acid to produce ribonucleic acid. The invention also relates to vectors and uses of purified or recombinant Kid/PemK endoribonucleases. | 03-19-2009 |
| 20090053714 | Gins gene expression as marker for actively cycling cells and cell cycle phase - The invention relates to a method of detecting an actively cycling cell in a sample, said method comprising determining the state of GINS gene expression within said cell, wherein detection of GINS gene expression in said cell indicates that said cell is actively cycling. Furthermore, the invention relates to methods for detecting an actively cycling cell in a subject, said method comprising assaying a sample from said subject for evidence of GINS gene expression, in particular when the sample is a body fluid such as urine. Preferable the GINS gene is PSFI or SLD | 02-26-2009 |
| 20090048434 | Compositions and methods relating to orthogonal ribosome mRNA pairs - Orthogonal ribosome orthogonal mRNA pairs are provided, as are methods for their selection involving a novel positive-negative selection approach, and methods for their use. Also provided are cellular logic circuits involving orthogonal ribosomes. | 02-19-2009 |
| 20080317705 | Promoting Wound Healing by Administering a Prostaglandin E and Granulocyte-Macrophage Colony Stimulating Factor - A method of promoting healing of a wound in a patient, the method comprising administering to the patient (i) a prostaglandin E (PGE) or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof. Use of (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof in the preparation of a medicament for promoting healing of a wound in a patient. A wound dressing, bandage or fibrin glue comprising (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof. | 12-25-2008 |
| 20080299618 | SINGLE DOMAIN LIGANDS, RECEPTORS COMPRISING SAID LIGANDS, METHODS FOR THEIR PRODUCTION AND USE OF SAID LIGANDS AND RECEPTORS - The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the productions of Ig-type molecules and said ligands or receptors, and the use of said ligand or receptors in therapy, diagnosis or catalysis. | 12-04-2008 |
| 20080286809 | Methods - A method for identifying a compound expected to be useful in modulating a WNK (With No Lysine Kinase) isoform protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a WNK isoform polypeptide on the substrate SPAK (STE20/SPS1-related Proline-Alanine-rich Kinase) or OSR1 (Oxidative Stress Response kinase-1) and (2) selecting a compound which modulates the said WNK isoform polypeptide protein kinase activity. Such a compound may be useful as an antihypertensive agent or for the treatment of, for example, Gordon's syndrome. | 11-20-2008 |
| 20080256147 | Method and a System for Storing Files - The present invention presents a method and a system of indexing, storing and retrieving data to and from multiple, remote and connected data sources over internet or intranet. Files are shredded into fixed number of strips using a defined pattern (shredding algorithm) and distributed randomly amongst the storage data sources (storage nodes). A unique index is maintained for each file and its strips along with corresponding storage nodes in a central file-storage database. On demand to retrieve a file, file-storage database is looked up for all relevant strips and storage nodes containing them. These file strips are then collected from all storage nodes and dressed back according to a defined anti-pattern (dressing algorithm) to the pattern used for shredding them. Failover control for storage nodes can be achieved by replicating each strip for a fixed number of storage nodes (replication factor). In case a storage node is not available, the next storage node containing the same strip can be used to get the strip back. | 10-16-2008 |
| 20080233558 | Inhibitors of viral entry screening method - In one aspect the invention relates to a method for identifying inhibitors or viral entry comprising providing an indicator cell wherein said cell expresses a reporter gene and wherein said cell is capable of supporting entry by an effector particle, providing a candidate inhibitor of viral entry, co-compartmentalizing said candidate inhibitor and said indicator cell, contacting said indicator cell with an effector particle, incubating to allow any effector particle entry to take place, and assaying said indicator cell for reporter gene activity, wherein detection of reporter gene activity identifies the candidate inhibitor as an inhibitor for viral entry. Preferably the effector particle is HIV, preferably the reporter gene is a CD | 09-25-2008 |
| 20080207509 | Scaffold - The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A sequence to improve it as a scaffold; preferably the Stefin A comprises a heterologous peptide insertion at the Leu 73 site. Furthermore, preferably the scaffold protein comprises a V48D mutation; preferably the scaffold protein comprises a G4W mutation. Preferably the scaffold comprises Leu73, V48D and G4W mutations. The invention also relates to the scaffold proteins themselves, in particular a stefin A polypeptide having the Leu73, V48D and G4W mutations, such as shown as SEQ ID NO: 1. The invention also relates to a method for identifying binding proteins and to peptide A (RLNKPLPSLPV) and its use in treating yeast infections. | 08-28-2008 |
| 20080206309 | ANTAGONISTS OF PROSTAGLANDIN RECEPTORS EP2 AND/OR EP4 FOR THE TREATMENT OF DYSMENORRHEA AND MENORRHAGIA - A method of treating menorrhagia and/or dysmenorrhoea in a patient the method comprising administering to the patient an antagonist of a prostaglandin EP2 and/or EP4 receptor. Preferably the patient is a human female. | 08-28-2008 |
